



IN THE UNITED STATES PATENT AND TRADEMARK OFFICES

In re Application of:

Kasid et al.

Application No. 10/075,994

Filed: February 15, 2002

For: CHEM

CHEMOSENSITIZING WITH LIPOSOMES CONTAINING

OLIGONUCLEOTIDES

Group Art Unit: 1615

Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT

Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

 \boxtimes

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date

In re Appln. of Kasid et al. Application No. 10/075,994

		rst Office Action on the merits; or (d) before the mailing of a first Office Action he filing of a request for continued examination under 37 CFR 1.114.
	37 CF	(a), (b), (c) or (d) above, but before the mailing date of a final action under R 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that vise closes prosecution in the application, and includes <i>one</i> of:
		the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
	\bigcap^{or}	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	under and o 37 CF	the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance 37 CFR 1.311, or an action that otherwise closes prosecution in the application, n or before payment of the issue fee, and includes the Statement under R 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as th in 37 CFR 1.17(p) (see "Fees" below).
	payme contain 37 CF: \$180 a NOTE: May 29	the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before ant of the issue fee, and within thirty days of receiving each item of information ned in the Information Disclosure Statement, and includes the Statement under R 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of as set forth in 37 CFR 1.17(p) (see "Fees" below). This is for original applications except applications for a design patent, filed on or after 2000, wherein a paper containing only an Information Disclosure Statement in compliance CFR 1.97 and 1.98 is being filed.
Copie	s of the	References
	Attach relevar an Eng action degree	s of the references listed on the enclosed Form 1449 are enclosed herewith, led to each reference not in the English language is a concise explanation of the nce pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or glish-language abstract, or an English-language version of the search report or by a foreign patent office in a counterpart foreign application indicating the of relevance found by the foreign office is being submitted in lieu of a concise ation of the relevance pursuant to 37 CFR 1.98(a)(3).
	A copy	y of the foreign search report is enclosed herewith.
	parent furnish submit The E accord Proced relied	eferences listed on the enclosed Form 1449 were previously identified in the application(s) of the present application, and copies of the references were need at that time. Accordingly, additional copies of the references are not need to herewith, so as not to burden the file with duplicate copies of references. Examiner is respectfully requested to carefully review the references in ance with the requirements set out in the Manual of Patent Examining ture. In accordance with 37 CFR 1.98(d), the details of the parent application(s) upon for an earlier filing date under 35 USC 120 in which copies of the nees were previously furnished are set out below:

In re Appln. of Kasid et al. Application No. 10/075,994

	U.S. APPLIC	CATIONS	Status (check one)			
U	.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
1.						
2.	<u></u>					
3.					<u> </u>	
State	ment under 37 CFR	1.97(e)				
	Information Discloration foreign patent office	hereby states that each sure Statement was find in a counterpart foreing of the Information	rst cited in a gn patent appl	ny commun ication not i	ication from a	
	Information Disclosoffice in a counte undersigned after material Information Disclosoffice.	hereby states that no sure Statement was cited rpart foreign patent ap taking reasonable inquire sure Statement was love than three months out.	l in a communi plication, and y, no item of i known to any	cation from to the known formation of individual	a foreign patent owledge of the contained in the designated in	
State	ment under 37 CFR	1.704(d)				
	Information Disclos office in a counterrany individual design	hereby states that each ure Statement was cited part application and that gnated in 37 CFR 1.56(Disclosure Statement.	in a communi this commun	cation from a cation was a	a foreign patent not received by	
Fees		÷				
	No fee is owed by the IDS Fee of \$18	ne applicant(s). 0 under 37 CFR 1.17(p)	is enclosed he	rewith.		
Metho	od of Payment of Fed	es	·			
		in the amount of \$ count No. 12-1216 in the is enclosed for that purp		. (A du	plicate copy of	
Autho	orization to Charge A	Additional Fees				
⊠ .	If any additional fee Deposit Account No for that purpose.)	es are owed in connection in the connection is a second connection of the connection in the connection in the connection is a second connection of the connection in the connection in the connection in the connection is a second connection of the connection in the connection in the connection is a second connection of the connection in the connection in the connection is a second connection of the connection in the connection is a second connection of the connection in the connection is a second connection of the connection in the connection is a second connection of the connection of the connection is a second connection of the connectio	on with this con e copy of this	mmunication communicat	, please charge ion is enclosed	

In re Appln. of Kasid et al. Application No. 10/075,994

Instructions as to Overpayment

Credit Account No. 12-1216.

M. Daniel Hefner, Reg. No. 41,826 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900 180 North Stetson Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Date: September 11, 2003 IDS (Revised 5/21/03)

SEP 1 5 200	13 મુ			Complete if Known				
Substitute for	form 1449A/B/PTO			Application Number	10/075,994	7)		
. INE	₽ PMATIONI	חופר	OSLIDE	Filing Date	February 15, 2002			
STATEMENT BY APPLICANT				First Named Inventor	Kasid et al.	(C) (S)		
517	AIEMENI B	SY AP	LICANI	Group Art Unit	Unassigned	Con 1		
	(Use as many she	ets as nece	essary)	Examiner Name	Unassigned	1, 6,		
Sheet	2	of	2	Attorney Docket Number	219604	19 O3		
		•				6		

			60	
		OTHER - NON PATENT LITERATURE DOCUMENTS	- 5	3,
	Dan	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Trans	slation
Examiner Initials	Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*
	AR	GOKHALE et al., "Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer," <i>Gene Therapy</i> , 4, 1289-1299 (1997)		:
,	AS	GOKHALE et al., "Antisense raf Oligodeoxyribonucleotide Is a Radiosensitizer In Vivo," Antisense & Nucleic Acid Drug Development, 9, 191-201 (1999)		,
	AT.	JAMES, "Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes," <i>Antiviral Chem. & Chemoth.</i> , 2, 191-214 (1991)		
	AU	KASID et al., "Effect of Antisense c-raf-1 on Tumorigenicity and Radiation Sensitivity of a Human Squamous Carcinoma," <i>Science</i> , 243, 1354-1356 (1989)		
	AV	LAPPALAINEN et al., "Comparison of Cell Proliferation and Toxicity Assays Using Two Cationic Liposomes," <i>Pharmaceutical Research</i> , 11(8), 1127-1131 (1994)	1.	·
	AW	LITIZINGER et al., "Fate of cationic liposomes and their complex with oligonucleotide in vivo," <i>Biochimica et Biophisica Acta</i> , 1281, 139-149 (1996)		
•	AX	MAHER et al., "Specific Hybridization Arrest of Dihydrofolate Reductase mRNA in Vitro Using Anti-sense RNA or Anti-sense Oligonucleotides," <i>Archives of Biochemistry and Biophysics</i> , 253, 214-220 (1987)		
	AY	MILNER et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," <i>Nature Biotechnology</i> , 15, 537-541 (1997)		
	AZ	PATEL et al., "Nucleotide Sequence Analysis of c-raf-1 cDNA and Promoter From a Radiation-Resistant Human Squamous Carcinoma Cell Line: Deletion Within Exon 17," <i>Molecular Carcinogenesis</i> , 8, 7-12 (1993)		
	ВА	SCHOFIELD et al., "Non-viral approaches to gene therapy," <i>Brit. Med. Bull.</i> , 51, 56-71 (1995)		
·	ВВ	SEUNG et al., "Genetic Radiotherapy Overcomes Tumor Resistance to Cytotoxic Agent," Cancer Research, 55, 5561-5565 (1995)		
	ВС	SOLDAATENKOV et al., "Inhibition of Raf-1 Protein Kinase by Antisense Phosphorothioate Oligodeoxyribonucleotide Is Associated with Sensitization of Human Laryngeal Squamous Carcinoma Cells to Gamma Radiation," Cancer J. Sci. Am., 3, 13-20 (1997)		
	BD	VERMA et al., "Gene therapy – promises, problems and prospects," <i>Nature</i> , 389, 239-242 (1997)		·
	-			
1.				
· ·	†	, , , , , , , , , , , , , , , , , , ,		
· · · · · · · · · · · · · · · · · · ·	·			
4, 1114				
				
		L		

Examiner Signature	Date Considered	·	,
	 	<u> </u>	·

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

CFD 1 5	is sign (*) inside this box	→ [-	E			
B	2003 6				Complete if Known	1
Substitute for fo	orm 1449A/B/PTO			Application Number	10/075,994	-47
THIE	PRMATION I	חופר	NOSUDE	Filing Date	February 15, 2002	
DAP.	TEMENT DY		DUSTRE	First Named Inventor	Kasid et al.	1/1/2
SIA	TEMENT BY	r AP	PLICANI	Group Art Unit	1615	6
	(Use as many sheet	s as nec	cessary)	Examiner Name	Unassigned	103 C
Sheet	1	of	2	Attorney Docket Number	219604	<u> </u>

				U.S. PATENT DOCUMENTS		300
		U.S. Patent Do	cument			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
	AA	5,283,185		Epand et al.	Feb. 1, 1994	
*	AB	5,641,662		Debs et al.	June 24, 1997	
	AC	5,696,277		Hostetler et al.	Dec. 9, 1997	·
	ΑD	5,756,122		Thierry et al.	May 26, 1998	
	ΑE	5,827,703		Debs et al.	Oct. 27, 1998	
	AF	5,952,229		Monia et al.	Sep. 14, 1999	
	AG	6,120,798		Allen et al.	Sep. 19, 2000	******
	АН	6,126,965		Kasid et al.	Oct. 3, 2000	
	Al	6,248,351	B1	Xing et al.	June 19, 2001	
	ΑJ	6,333,314	B1	Kasid et al.	Dec. 25, 2001	
•	ļ					
•			 			
	ļ		 			
						
	I	l			1	

				FORE	IGN PATENT DOCUMENTS			
		Foreign Patent Document				1	Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	AK	wo	95/11670		THE LIPOSOME COMPANY, INC.	May 4, 1995		
	AL	wo	95/32987		MACEUTICALS, INC.	Dec. 7, 1995		
				ļ				
				 				
		 [-				
				 				

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.			
	АМ	BRANCH, "A Good Antisense Molecule is Hard to Find," <i>TIBS</i> , 23, 45-50 (1998)		
	AN	CROOKE, "Antisense Research and Application," Springer-Verlag, 1, 1-50 (1998)		
	AO	CRYSTAL, "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," Science, 270, 404-410 (1995)		
	AP	FRIEDMANN, "Overcoming the Obstacles to Gene Therapy," Science America, June, 96-101 (1997)		
	AQ	GOKHALE et al., "Enhanced inhibition of Raf-1 kinase by liposomal antisense raf oligodeoxyribonucleotide in human squamous carcinoma cells," American Asso. Cancer Research, 37, Poster Section 6 #2807 (1996)		

Evaminar Cianatura	Data Canaidared	
Examiner Signature	Date Considered	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).